Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 28, 2020; 26(32): 4846-4856
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4846
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4846
Table 1 Demographic and clinical characteristics of patients with Helicobacter pylori infection
Variable | Cases (n) | Percentage |
Overall cases | 2610 | |
Gender | ||
Male | 1088 | 41.70% |
Female | 1522 | 58.30% |
Age, range (yr) | ||
< 30 | 582 | 22.30% |
30-40 | 576 | 22.10% |
40-50 | 478 | 18.30% |
50-60 | 528 | 20.20% |
> 60 | 446 | 17.10% |
Chief complaint | ||
Upper abdominal pain | 406 | 15.60% |
Abdominal distension | 643 | 24.60% |
Nausea | 138 | 5.30% |
Acid regurgitation or heartburn | 250 | 9.60% |
Bitter taste in mouth | 157 | 6.00% |
Belching | 224 | 8.60% |
Increased stool frequency | 143 | 5.50% |
Others | 152 | 5.80% |
No symptoms | 1309 | 50.20% |
Received gastroscopy | 1390 | 53.30% |
Endoscopic and pathological findings | ||
Peptic ulcer | 244 | 9.30% |
Pre-neoplastic lesions | 416 | 15.90% |
MALT lymphoma or gastric cancer | 17 | 0.70% |
Eradication attempts | ||
Primary | 2237 | 85.70% |
Rescue | 373 | 14.30% |
Table 2 Eradication rates of specific Helicobacter pylori regimens classified by proton pump inhibitor
PPI | Successful eradication (n) | Total (n) | Eradication rate (%) | 95%CI (%) |
Esomeprazole | 566 | 698 | 81.1 | 78.2-84.0 |
Non-esomeprazole PPIs | 1433 | 1912 | 74.9 | 73.0-76.8 |
Rabeprazole | 657 | 836 | 78.6 | 75.8-81.4 |
Lansoprazole | 43 | 55 | 78.2 | 67.3-89.1 |
Pantoprazole | 449 | 607 | 74.0 | 70.5-77.5 |
Omeprazole | 284 | 414 | 68.6 | 64.1-73.1 |
Table 3 Subgroup comparison of eradication rates
Antibiotic regimen | Successful eradication (n) | Total (n) | Eradication rate (%) | 95%CI (%) | |
Primary | Total | 1751 | 2237 | 78.3 | 76.6-80.0 |
Amoxicillin plus clarithromycin | 980 | 1166 | 84.0 | 81.9-86.1 | |
Amoxicillin plus levofloxacin | 47 | 54 | 87.0 | 78.1-96.0 | |
Amoxicillin plus furazolidone | 8 | 11 | 72.7 | 46.4-99.0 | |
Clarithromycin plus metronidazole | 61 | 112 | 54.5 | 45.2-63.7 | |
Clarithromycin plus levofloxacin | 647 | 871 | 74.3 | 71.4-77.2 | |
Clarithromycin plus furazolidone | 7 | 20 | 35.0 | 14.1-55.9 | |
Levofloxacin plus furazolidone | 1 | 3 | 33.3 | 0.0-86.7 | |
Rescue | Total | 248 | 373 | 66.5 | 61.7-71.3 |
Amoxicillin plus clarithromycin | 81 | 105 | 77.1 | 69.1-85.2 | |
Amoxicillin plus levofloxacin | 13 | 22 | 59.1 | 38.5-79.6 | |
Amoxicillin plus furazolidone | 42 | 52 | 80.8 | 70.1-91.5 | |
Clarithromycin plus metronidazole | 20 | 36 | 55.6 | 39.3-71.8 | |
Clarithromycin plus levofloxacin | 73 | 128 | 57.0 | 48.5-65.6 | |
Clarithromycin plus furazolidone | 8 | 14 | 57.1 | 31.2-83.1 | |
Levofloxacin plus furazolidone | 11 | 16 | 68.8 | 46.0-91.5 |
Table 4 Univariate and multivariate analyses of risk factors for eradication failure
Variable | Univariate analysis | Multivariate analysis | |||||
OR | 95%CI | P value | OR | 95%CI | P value | ||
Gender | Male | 1 (Reference) | |||||
Female | 1.202 | 0.998-1.447 | 0.052 | ||||
Age | 1.018 | 1.011-1.024 | < 0.001 | 1.014 | 1.008-1.021 | < 0.001 | |
Eradication attempts | Primary | 1 (Reference) | 1 (Reference) | ||||
Rescue | 1.816 | 1.432-2.302 | < 0.001 | 1.538 | 1.179-2.007 | 0.002 | |
Antibiotic regimens | Amoxicillin plus clarithromycin | 1 (Reference) | 1 (Reference) | ||||
Amoxicillin plus levofloxacin | 1.347 | 0.761-2.385 | 0.306 | 1.167 | 0.654-2.084 | 0.601 | |
Amoxicillin plus furazolidone | 1.314 | 0.701-2.461 | 0.394 | 0.982 | 0.505-1.911 | 0.958 | |
Clarithromycin plus metronidazole | 4.179 | 2.928-5.966 | < 0.001 | 3.139 | 2.125-4.637 | < 0.001 | |
Clarithromycin plus levofloxacin | 1.958 | 1.599-2.397 | < 0.001 | 1.863 | 1.517-2.287 | < 0.001 | |
Clarithromycin plus furazolidone | 6.4 | 3.200-12.797 | < 0.001 | 5.748 | 2.834-11.655 | < 0.001 | |
Levofloxacin plus furazolidone | 2.947 | 1.147-7.574 | 0.025 | 2.115 | 0.798-5.605 | 0.132 | |
PPIs | Esomeprazole | 1 (Reference) | 1 (Reference) | ||||
Rabeprazole | 1.168 | 0.909-1.502 | 0.225 | 1.138 | 0.879-1.473 | 0.327 | |
Lansoprazole | 1.197 | 0.614-2.332 | 0.598 | 1.262 | 0.638-2.496 | 0.504 | |
Pantoprazole | 1.509 | 1.161-1.961 | 0.002 | 1.398 | 1.067-1.831 | 0.015 | |
Omeprazole | 1.963 | 1.482-2.600 | < 0.001 | 1.513 | 1.113-2.056 | 0.008 |
- Citation: Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856
- URL: https://www.wjgnet.com/1007-9327/full/v26/i32/4846.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i32.4846